Research programme: spinal cord injury therapies - AnaMar

Drug Profile

Research programme: spinal cord injury therapies - AnaMar

Alternative Names: AM 250; Project AM 250 - SCI

Latest Information Update: 17 Jun 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnaMar Medical
  • Class Small molecules
  • Mechanism of Action Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Spinal cord injuries

Most Recent Events

  • 25 Jul 2008 Preclinical development is ongoing
  • 25 Jul 2006 Preclinical trials in Spinal cord injuries in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top